Actively Recruiting
Assessment of Sexual Well-being in Patients With Gynecologic Cancer and Their Partners: the ONCOSEX Study
Led by Casa di Cura Dott. Pederzoli · Updated on 2026-04-29
200
Participants Needed
6
Research Sites
104 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Study type and design This is an observational, exploratory, prospective, longitudinal (cohort), multicenter, non-profit study. Its purpose is to observe changes in sexual function over time without modifying standard clinical care pathways. Background and rationale Sexual dysfunctions and the psychological impact of gynecological cancers are often underestimated in clinical practice, despite the World Health Organization recognizing sexual health as a fundamental right. Cultural, personal, and educational barriers frequently hinder an open and systematic discussion of sexual health. Available literature highlights a significant deterioration in sexual quality of life and couple relationships among these patients; however, clear guidance on validated assessment tools and structured sexual counseling pathways is still lacking. Study objectives Primary objective: to evaluate whether and how sexual function questionnaire scores in patients and their partners change over time at different assessment time points. Secondary objective: to identify the proportion of patients and partners who would perceive sexual counseling as useful, as well as the preferred timing for such support. Endpoints Primary endpoint: variation in Female Sexual Function Index (FSFI) scores in female patients and International Index of Erectile Function (IIEF-15) scores in male partners between assessment time points (T0-T1, T1-T2, T0-T2). Secondary endpoint: perceived usefulness of sexual counseling support and preferred timing, based on questionnaire responses. Procedures and assessment timeline Patients are enrolled at the time of diagnosis communication (T0). The same questionnaire is administered again six months after the start of treatment (T1) and twelve months after completion of therapy or surgery (T2). Participation requires written informed consent, and all data are collected in a pseudo-anonymized format. Partners are enrolled and assessed at the same time points. Assessment tools Patients: the validated Female Sexual Function Index (FSFI) questionnaire, plus an additional structured section exploring sexual experience, satisfaction, and difficulties. Partners: the IIEF-15 questionnaire for male partners; for female partners, the same instruments used for patients are administered. Collected variables Sociodemographic and clinical data, lifestyle habits, sleep quality, marital status, parity, ongoing or previous therapies, and FSFI and IIEF-15 questionnaire scores. Sample size A total of 200 patients and 200 corresponding partners are expected to be enrolled. Statistical analysis Data will be analyzed descriptively and longitudinally across the three time points. The primary analysis will use linear mixed-effects models for repeated measures, including random effects for subjects and fixed effects for time and relevant clinical covariates. Predefined subgroup analyses are planned. Statistical significance is set at p \< 0.05.
CONDITIONS
Official Title
Assessment of Sexual Well-being in Patients With Gynecologic Cancer and Their Partners: the ONCOSEX Study
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients diagnosed with gynecological cancer: malignant ovarian tumor, ovarian tumor of uncertain behavior, cervical cancer, endometrial cancer, uterine sarcoma, vulvar cancer, vaginal cancer
- Sexually active
- Women who have a partner
- Aged between 18 and 75
- Women of any sexual orientation
- Understanding and knowledge of the Italian language
- Signing of the informed consent form
- Signing of the informed consent form by the partner
You will not qualify if you...
- Benign gynecological conditions
- Age less than 18 or greater than 75
- Virgins or women who are no longer sexually active
- Women with psychiatric or neurological disorders
- Women or partners who have already undergone sexual counseling or sex therapy
- Women who are unable to sign the informed consent form for the study
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 6 locations
1
IRCCS Azienda ospedaliero-universitaria di Bologna - Policlinico Sant'Orsola
Bologna, Bologna, Italy, 40138
Not Yet Recruiting
2
IEO - Istituto Europeo di Oncologia
Padova, Padova, Italy, 20141
Not Yet Recruiting
3
Policlinico Universitario Fondazione Agostino Gemelli
Roma, Roma, Italy, 0630151
Not Yet Recruiting
4
IRCCS Materno infantile Burlo Garofolo
Trieste, Trieste, Italy, 34137
Not Yet Recruiting
5
Presidio Ospedaliero Universitario "Santa Maria della Misericordia"
Udine, Udine, Italy, 33100
Not Yet Recruiting
6
Ospedale P. Pederzoli Casa di Cura Privata S.p.A.
Peschiera del Garda, Verona, Italy, 37019
Actively Recruiting
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here